《大行報告》瑞信降中國中藥(00570.HK)評級至「中性」 目標價上調至5.1元
瑞信發表研究報告指中國中藥(00570.HK)去年收入大致符預期,純利略勝該行預期;管理層指引今年收入增長約20%。報告稱,自1月底母企對其潛在私有化消息傳出以來,未有任何更新。
報告稱,中國中藥顆粒劑板塊仍是主要引擎,料維持行業領導地位,並達到更高的顆粒劑標準。該行上調其今明兩年盈測1%及5%,反映更高毛利率預測,由於私有化消息傳出,其本年至今股價累升約20%,該行下調其投資評級由「跑贏大市」降至「中性」,目標價則由4.3元升至5.1元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.